Perspective Therapeutics
CATX
39 hedge funds and large institutions have $5.79M invested in Perspective Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
0.11% less ownership
Funds ownership: 1.23% → 1.12% (-0.11%)
13% less funds holding
Funds holding: 45 → 39 (-6)
15% less capital invested
Capital invested by funds: $6.78M → $5.79M (-$993K)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TMWM
Taylor & Morgan Wealth Management
Flint,
Michigan
|
+$76.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$46.3K |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
+$18.2K |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.6K |
| 5 |
Two Sigma Advisers
New York
|
+$9.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HPWM
Highland Private Wealth Management
Bellevue,
Washington
|
-$377K |
| 2 |
Renaissance Technologies
New York
|
-$206K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$53.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$44.2K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24K |
CATX Hedge Fund Activity: Q1 2022 in Review
39 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q1 2022, worth a combined $5.79M — down 15% from $6.78M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CATX and 3 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was Taylor & Morgan Wealth Management, adding an estimated $76.6K. The largest seller was Highland Private Wealth Management, exiting entirely with an estimated $377K sold.
- 39 institutional investors held Perspective Therapeutics (CATX) as of Q1 2022, down from 45 in Q4 2021.
- Funds reported $5.79M of Perspective Therapeutics stock for Q1 2022, down 15% quarter-over-quarter.
- 3 funds opened new Perspective Therapeutics positions in Q1 2022 and 9 closed out, a net change of -6 holders.
- The largest Perspective Therapeutics buyer in Q1 2022 was Taylor & Morgan Wealth Management, an estimated $76.6K added.
- The largest Perspective Therapeutics seller in Q1 2022 was Highland Private Wealth Management, an estimated $377K sold.
Based on aggregated 13F filings for Q1 2022.